×

99: Building a medical company without a specialist background | Clare Brenner of Myogenes

09 Jul 2024 / Podcast Tax Advantaged

By Dr Brian Moretta

In this episode of the EIS Navigator we get a great founder story. Despite not having a medical background, Clare Brenner founded Myogenes, which specialises in pharmocogenetic testing. She has a very personal story about her motivation for initially focusing on mental health to begin with, as well as her experiences in starting in a new area.

In the discussion, Clare talks about:

  • How she found a good area to work on;
  • The initial focus on clozapine;
  • Why she seeks out the best people to work with;
  • The challenges of getting initial funding;
  • How patient advocacy is playing a role;
  • Making a business case to convince the NHS;
  • Moving into the US market;
  • Where we are in developing personalised medicine.

Clare’s story is both inspiring and insightful.

Please email [email protected] if you have any questions or comments on The EIS Navigator.

Never miss an episode – click here to subscribe to The EIS Navigator on most popular services. 

Listen now

Links

Visit the Myogenes website.

T: +44 (0)20 8387 1266

Suggested book

The Diary of a CEO by Steven Bartlett

Clare Brenner, CEO and Co-Founder of Myogenes, began her working career at the BBC, moving from radio to television and then to writing and producing. Her interest in genetics started in 2010, working for a private hospital and launching their DNA testing programme. She started on her own in 2016 and has dedicated the last six years to becoming expert in the field of genetics and forming her own company.

Disclaimer

Please note this podcast/interview does not constitute a financial promotion and is provided for informational purposes and should not be construed as an invitation or offer to buy or sell any investments. Please be aware that investments into unquoted companies are high risk, long term and illiquid investments.  Your capital is at risk. Past performance is not a reliable indicator of future performance.  Target returns are not guaranteed and forward looking statements are illustrative only and must not be relied upon. Investors should only invest on the basis of reading the full offer documentation. Listeners must make their own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein.